Cargando…
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Diabetic Nephropathy Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790190/ https://www.ncbi.nlm.nih.gov/pubmed/27047804 http://dx.doi.org/10.15171/jnp.2016.02 |
_version_ | 1782420957898473472 |
---|---|
author | Esmaili, Haydarali Mostafidi, Elmira Mehramuz, Bahareh Ardalan, Mohammadreza Mohajel-Shoja, Mohammadali |
author_facet | Esmaili, Haydarali Mostafidi, Elmira Mehramuz, Bahareh Ardalan, Mohammadreza Mohajel-Shoja, Mohammadali |
author_sort | Esmaili, Haydarali |
collection | PubMed |
description | Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each other and complicate the condition. Evidence Acquisition: Directory of Open Access Journals (DOAJ), EMBASE, Google Scholar, PubMed, EBSCO, and Web of Science with keywords relevant to; Hemophagocytic syndrome, macrophage activation syndrome, interferon-gamma and thrombotic microangiopathy, have been searched. Results: Viral infection, rheumatologic disease and malignancies are the main underlying causes for secondary HPS. calcineurin inhibitors and viral infections are also the main underlying causes of TMA in transplant recipients. In this review, we discussed a 39-year-old male who presented with pancytopenia and renal allograft dysfunction. With the diagnosis of HPS induced TMA his renal condition and pancytopenia improved after receiving intravenous immunoglobulin (IVIG) and plasmapheresis therapy. Conclusions: HPS is an increasingly recognized disorder in the realm of different medical specialties. Renal involvement complicates the clinical picture of the disease, and this condition even is more complex in renal transplant recipients. We should consider the possibility of HPS in any renal transplant recipient with pancytopenia and allograft dysfunction. The combination of HPS with TMA future increases the complexity of the situation. |
format | Online Article Text |
id | pubmed-4790190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Society of Diabetic Nephropathy Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-47901902016-04-04 An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) Esmaili, Haydarali Mostafidi, Elmira Mehramuz, Bahareh Ardalan, Mohammadreza Mohajel-Shoja, Mohammadali J Nephropathol Review Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each other and complicate the condition. Evidence Acquisition: Directory of Open Access Journals (DOAJ), EMBASE, Google Scholar, PubMed, EBSCO, and Web of Science with keywords relevant to; Hemophagocytic syndrome, macrophage activation syndrome, interferon-gamma and thrombotic microangiopathy, have been searched. Results: Viral infection, rheumatologic disease and malignancies are the main underlying causes for secondary HPS. calcineurin inhibitors and viral infections are also the main underlying causes of TMA in transplant recipients. In this review, we discussed a 39-year-old male who presented with pancytopenia and renal allograft dysfunction. With the diagnosis of HPS induced TMA his renal condition and pancytopenia improved after receiving intravenous immunoglobulin (IVIG) and plasmapheresis therapy. Conclusions: HPS is an increasingly recognized disorder in the realm of different medical specialties. Renal involvement complicates the clinical picture of the disease, and this condition even is more complex in renal transplant recipients. We should consider the possibility of HPS in any renal transplant recipient with pancytopenia and allograft dysfunction. The combination of HPS with TMA future increases the complexity of the situation. Society of Diabetic Nephropathy Prevention 2016-01 2015-07-15 /pmc/articles/PMC4790190/ /pubmed/27047804 http://dx.doi.org/10.15171/jnp.2016.02 Text en © 2016 The Author(s) Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Esmaili, Haydarali Mostafidi, Elmira Mehramuz, Bahareh Ardalan, Mohammadreza Mohajel-Shoja, Mohammadali An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title_full | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title_fullStr | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title_full_unstemmed | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title_short | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
title_sort | update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790190/ https://www.ncbi.nlm.nih.gov/pubmed/27047804 http://dx.doi.org/10.15171/jnp.2016.02 |
work_keys_str_mv | AT esmailihaydarali anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mostafidielmira anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mehramuzbahareh anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT ardalanmohammadreza anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mohajelshojamohammadali anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT esmailihaydarali updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mostafidielmira updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mehramuzbahareh updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT ardalanmohammadreza updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome AT mohajelshojamohammadali updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome |